Relation of growth hormone response to growth hormone-releasing hormone before weaning and postweaning growth performance in beef calves

Previously, GH response to GHRH challenge at weaning has been shown to be indicative of ADG during a standard postweaning growth performance test in Angus cattle. In this study, we tested the hypothesis that GH response to GHRH before weaning would predict postweaning ADG. Bulls with the highest and lowest GH responses to GHRH over a 3-yr period, relative to their contemporaries, were used as sires, to allow for examination of the persistence of GH response to GHRH through selection. The selected calves in this study were sired by one of four Angus bulls chosen based on their GH response to GHRH (high response, n = 2; low response, n = 2). Forty-nine Angus calves (bulls, n = 24; heifers, n = 25) were challenged with GHRH at approximately 60, 105, and 150 d of age and at weaning (219 d; SD = 25). Blood samples were taken immediately prior to and 10 min following an i.v. clearance dose of 4.5 microg of GHRH/100 kg BW and, 2 h later, immediately prior to and 10 min following a challenge dose of either 1.5 or 4.5 microg of GHRH/100 kg BW. Two hours later, the procedure was repeated, with each calf receiving the other challenge dose. Body weight was measured every 28 d and ADG was calculated over a 140-d growth performance test (heifers and bulls maintained separately). Data were log-transformed for statistical analyses. In the selected bulls and heifers, response of GH to 1.5 microg of GHRH/100 kg BW at 60 and 105 d of age was positively related (P < 0.05) to postweaning ADG. Response to 4.5 microg of GHRH/100 kg BW at 105 d of age and at weaning was positively related (P < 0.01) to postweaning ADG. Inclusion of sire in the analysis improved the relationship between GH response and ADG for calves of sires with high GH responses from R2 = 0.18 (P = 0.01) to R2 = 0.33 (P = 0.02). When the GH response to GHRH of the unselected calves at weaning was added to the data from the selected animals and analyzed, the GH response of the bulls was related to postweaning ADG (R2 = 0.09; P = 0.04). In conclusion, GH response to GHRH as early as 60 d of age is indicative of postweaning ADG in beef cattle. In addition, the relationship between GH response to GHRH and postweaning ADG is improved with selection for greater GH response to GHRH.     

Use of growth hormone response to growth hormone-releasing hormone to determine growth potential in beef heifers.

The response of GH to GHRH at weaning is known to predict postweaning growth and body composition in beef bulls. The objective of this study was to determine whether GH response to a challenge of GHRH and plasma IGF-I can predict growth rate and body composition in the beef heifer. Growth hormone response to a challenge with two doses of GHRH was measured in 67 Angus heifers averaging 225 d of age (SD = 21) and 217 kg BW (SD = 32). Blood samples were collected at 0 and 10 min relative to an initial "clearance dose" (4.5 micrograms GHRH/100 kg BW) and again, 3 h later, relative to a challenge dose (1.5 or 4.5 micrograms GHRH/100 kg BW). Each animal received each of the two challenge doses, which were randomly assigned across 2 d of blood collection. Serum GH concentration was measured by RIA. Plasma was collected every 28 d during a 140-d growth test and assayed for IGF-I by RIA. Body weight was measured every 28 d and hip height was measured at weaning and at the end of a 140-d growth test. Average daily gain was calculated on d 140 of the growth test and body composition measurements were estimated by ultrasound 2 wk after completion of the growth test. Responses to the two GHRH challenges were dose-dependent (P < 0.05). Average daily gain tended to be related to GH response to the 1.5 micrograms GHRH/100 kg BW dose (R2 = 0.05; P = 0.06), but no relationship was observed at the 4.5 micrograms GHRH/100 kg BW dose (R2 = 0.00; P = 0.93). An inverse relationship (R2 = 0.06; P = 0.02) was observed between response to the 1.5 micrograms GHRH/100 kg BW dose and intramuscular fat percentage. Mean plasma IGF-I concentration was positively associated with ADG (R2 = 0.06; P < 0.01). Growth hormone response to GHRH is modestly related to body composition but not to ADG in weanling beef heifers and likely has limited use in evaluation of growth performance in replacement beef heifers.     

Growth performance and carcass composition of lambs infused for 28 days with a growth hormone-releasing factor analogue.

A human growth hormone-releasing factor analogue, [DesNH2Tyr1,D-Ala2,Ala15]hGRF(1-29)NH2 (GRF-A), was infused s.c. into lambs for 28 d to determine its effects on growth performance and carcass composition. Twenty crossbred wethers weighing 47.0 +/- .5 kg were implanted with 7-d osmotic minipumps at weekly intervals. Minipumps contained either vehicle (dimethyl sulfoxide:H2O, 1:1) or GRF-A, released at a rate of 208 pmol (or .7 micrograms).h-1.kg-1. During the infusion period, plasma GH levels were increased (P less than .01) in GRF-A-treated wethers compared with control wethers (15.0 vs 9.3 ng/ml) and were higher on days that closely followed minipump implantation. Plasma IGF-I and hepatic IGF-I RNA concentrations were similar in lambs of both groups. Analogue treatment improved feed conversion (4.9 vs 5.8 kg dry matter/kg gain, P less than .05), increased average daily gain (.35 vs .30 kg, P = .05) and had no effect on feed intake, wool growth and body, carcass, selected organ and pituitary weights. Carcasses from GRF-A-infused lambs had less adjusted fat depth, a lower percentage of fat and a higher percentage of protein (P less than .05) than carcasses from control lambs. Magnitude of most effects of GRF-A on carcass measurements were correlated with the mean GH level that a lamb had during the infusion period. In conclusion, s.c. infusion of GRF-A improved feed utilization and altered carcass composition of feeder lambs in a relatively short period of time (28 d).     

Sexual dimorphic porcine pituitary response to growth hormone-releasing hormone

The aim of this study was to compare growth hormone (GH) response of barrows and gilts to porcine growth hormone-releasing hormone (pGRH) at the pituitary level. Anterior pituitary cells from barrows and gilts responded to pGRH in a dose-dependent manner. The median effective pGRH concentration (EC50) which stimulated GH release from cells of barrows was greater (P less than .05) than that for cells obtained from intact female siblings. Maximal pGRH mediated GH secretion from barrows was not different (P greater than 0.05) than that from gilt stimulated cells. These data demonstrate that somatotrophs of growing peripubertal gilts are more responsive to pGRH stimulation than are cells from their castrated male siblings. This difference could be caused by castration of the neonatal male.     

Effect of bovine somatotropin on the growth rate, hormone profiles and carcass composition of Holstein bull calves

A study was conducted to determine the effects of BST on the growth rate, hormone profiles and carcass composition of preweaned Holstein bull calves. Injection of BST resulted in increased average daily gains and feed intakes (P less than .05) compared to that of control animals. This increased rate of gain coupled with increased intakes resulted in identical feed conversion efficiencies between treatments. Fractional weights (organ weight/body weight) of selected organs and tissues were unaffected by BST treatment. Carcass fat percentage was reduced in BST-treated calves (28.1 +/- 1.18% and 32.8 +/- 1.84% for BST and controls groups respectively, P less than .05) while no differences were seen for carcass DM, CP, ash or gross energy content. Plasma BST levels were higher (P less than .0001) in BST treated calves while plasma IGF-1 levels were not different between treatments. Plasma IGF-1 concentrations correlated (P less than .0001, R = .71) with average daily gains. The results of this trial suggest that growth responses are inducible with BST in young calves (7 days to 3 months).     

Stimulation of pig growth performance by porcine growth hormone and growth hormone-releasing factor

The current study was undertaken to determine the effects of human growth hormone-releasing factor [hpGRF-(1-44)-NH2] on growth performance in pigs and whether this response was comparable to exogenous porcine growth hormone (pGH) treatment. Preliminary studies were conducted to determine if GRF increased plasma GH concentration after iv and im injection and the nature of the dose response. Growth hormone-releasing factor stimulated the release of pGH in a dose-dependent fashion, although the individual responses varied widely among pigs. The results from the im study were used to determine the dose of GRF to use for a 30-d growth trial. Thirty-six Yorkshire-Duroc barrows (initial wt 50 kg) were randomly allotted to one of three experimental groups (C = control, GRF and pGH). Pigs were treated daily with 30 micrograms of GRF/kg body weight by im injection in the neck. Pigs treated with pGH were also given 30 micrograms/kg body weight by im injection. Growth rate was increased 10% by pGH vs C pigs (P less than .05). Growth rate was not affected by GRF; however, hot and chilled carcass weights were increased 5% vs C pigs (P less than .05). On an absolute basis, adipose tissue mass was unaffected by pGH or GRF. Carcass lipid (percent of soft-tissue mass) was decreased 13% by GRF (P less than .05) and 18% by pGH (P less than .05). Muscle mass was significantly increased by pGH but not by GRF. There was a trend for feed efficiency to be improved by GRF; however, this was not different from control pigs. In contrast, pGH increased feed efficiency 19% vs control pigs (P less than .05). Chronic administration of GRF increased anterior pituitary weight but did not affect pituitary GH content or concentration. When blood was taken 3 h post-injection, both GRF- and pGH-treated pigs had lower blood-urea nitrogen concentrations. Serum glucose was significantly elevated by both GRF and pGH treatment. This was associated with an elevation in serum insulin. These results indicate that increasing the GH concentration in blood by either exogenous GH or GRF enhances growth performance. The effects of pGH were more marked than for GRF. Further studies are needed to determine the optimal dose of GRF to administer in growth trials and the appropriate pattern of GRF administration in order to determine whether GRF will enhance pig growth performance to the extent that exogenous pGH does.     

Regulation of growth hormone-releasing hormone and somatostatin from perifused,bovine hypothalamic slices. III. Reciprocal feedback between growth hormone-releasing hormone and somatostatin

An in vitro perifusion system for bovine hypothalamic tissue was used to determine if growth hormone-releasing hormone (GHRH) and somatostatin (SRIF) modulate each other's release, and whether SRIF mediates D₁-agonist-induced suppression of GHRH in cattle. Up to three sagittal slices (600 μm) of bovine hypothalamus, immediately parallel to the midline, were cut in an oxygenated balanced salt solution at 4° C, placed in 5 cc syringe barrels, and perifused at 37° C with oxygenated minimum essential medium-α at a flow rate of 0.15 ml/min. Three experiments were conducted, and medium effluent was collected every 20 min before (two samples), during (one or three samples), and after (six samples) treatment. Areas under GHRH and SRIF response curves (AUC), adjusted by covariance for pretreatment values, were calculated from samples collected during the treatment/post-treatment period. Perifusion of SRIF at 10⁻⁶ M and 10⁻⁴ M decreased AUC for GHRH from 86.3 (control) to 65.4 and 59.5 ± 6.3 ng · ml⁻¹ min, but 10⁻⁸ M SRIF was ineffective. Relative to controls, 10⁻⁸, 10⁻⁶, and 10⁻⁴ M GHRH increased release of SRIF 190, 675, and 1,135%, respectively. Activation of D₁ receptors with 10⁻⁶ M SKF 38393 increased AUC for SRIF from 12.5 ng · ml⁻¹ min (control) to 484.9 ng · ml⁻¹ min and decreased AUC for GHRH from 36.4 ng · ml⁻¹ min (control) to 18.2 ng · ml⁻¹ min. Blockade of SRIF action with a SRIF antagonist, cyclo-[7-aminoheptanoyl-phe-d-trp-lys-thr(bzl)], increased release of GHRH 1.9-fold. In addition, the SRIF antagonist blocked SKF 38393-induced suppression of GHRH. We concluded that GHRH and SRIF interact within the bovine hypothalamus/pituitary stalk to modulate the release of the other. Moreover, SRIF mediates the inhibitory effects of activation of D₁ receptors on release of GHRH in cattle.     

Growth hormone response to growth hormone-releasing hormone in beef cows divergently selected for milk production

In dairy cattle, increased circulating growth hormone has been associated with selection for greater milk yield. This study tested the hypothesis that beef cows divergently selected for milk production would have differing GH responses to a challenge dose of GHRH. Growth hormone response to a challenge of GHRH was measured in 36 Angus-sired cows ranging from 6 to 10 yr of age. The cows were classified as high milking (n = 16) or low milking (n = 20), on the basis of their sires' milk EPD. Mean milk EPD (in kilograms) were 16.6 and -14.4 for high and low milking cows, respectively. Milk production was estimated by the weigh-suckle-weigh procedure. Blood samples were taken immediately before and 10 min after a clearance dose of 4.5 microg of GHRH/100 kg BW (injected i.v.) and, 3 h later, immediately before and 10 min after a challenge dose of either 1.5 or 4.5 microg of GHRH/100 kg BW. Each animal received both challenge doses, and the doses were randomly assigned across 2 d of blood collection. Serum concentrations of GH and IGF-I were measured by RIA. Serum IGF-I was measured in the baseline blood sample on d 1 of blood collection. A positive relationship (r = 0.35; P = 0.03) was observed between the cows' rankings for each dose of GHRH; that is, high responders to the low dose were high responders to the high dose. Growth hormone response to the 4.5 microg/100 kg BW challenge dose of GHRH was positively related to sire milk EPD (R2 = 0.09; P = 0.03). Response of GH to the 1.5 microg GHRH/100 kg BW challenge dose also tended to be related (P = 0.08) to sire milk EPD of high milking cows. In addition, IGF-I concentrations of high milking cows were inversely related (R2 = 0.24; P = 0.04) to sire milk EPD. Growth hormone response to GHRH challenge may have potential as an additional tool in the evaluation of milk production in beef cattle.     

Serum growth hormone release in response to a growth hormone-releasing factor analog during and after anesthesia in pigs.

The objective of this study was to evaluate the time course for full recovery of the growth hormone governing system and somatocrinin response after anesthesia. Sixteen Yorkshire gilts aged 32 weeks were divided into three groups: saline (n = 6), anesthesia + saline (n = 5) and anesthesia + somatocrinin (n = 5). Under anesthesia, the area under the growth hormone curve was increased (P less than 0.05) from 1172 +/- 184 to 2807 +/- 1002 ng.min.mL-1, and a more consistent growth hormone response to somatocrinin was observed; all animals responded immediately, while only three out of five did so four hours before anesthesia. Sixteen and 40 hours after anesthesia, basal and stimulated growth hormone levels were comparable to those of unanesthetized controls, suggesting a prompt recovery from the effects of anesthesia. These data indicate that anesthetized pigs release higher quantities of growth hormone and have a more consistent growth hormone response to somatocrinin. A full recovery of basal and somatocrinin-induced growth hormone release was observed as soon as 16 hours after anesthesia.     

Serum growth hormone and nitrogen metabolism responses in young bull calves infused with growth hormone-releasing factor for 20 days

Intravenous infusion of growth hormone (GH)-releasing factor (GRF) sustains elevated serum GH for at least 5 days in young Holstein steers, but the effects of extended infusion of GRF on serum GH and nitrogen (N) metabolism have not been determined. Thirteen Dutch-Friesian bull calves (148 +/- 1.5 kg) were assigned randomly to receive daily either 0 or 3.6 mg GRF (hGRF1-44NH2; U-68420) in saline as a continuous infusion for 20 days. Calves were fed milk replacer twice daily while housed indoors in wooden-slatted floor box crates (metabolism cages). Nitrogen determinations were made on daily feed, feces, and urine samples which were pooled for days 9 to 14 of treatment. Concentrations of GH were quantified in blood samples collected at 20 min intervals for 8 hr on day 1, 10 and 20. The infusion of GRF increased baseline GH (P less than .07), the number of GH pulses (P less than .0001), the amplitude of the GH pulses (P less than .001), and area under the GH response curve (P less than .0002). Within GRF-infused calves baseline GH (P less than .0001) and area under the GH response curve (P less than .006) were greater on day 20 than on day 1 or 10 (day X treatment interaction, P less than .04). Area under the GH response curve was similar on each sampling day in saline-infused calves, but baseline GH was higher (P less than .03) on day 20 than either day 1 or 10. Infusion of GRF increased episodic GH secretion in spite of limited pulsatile activity in saline-infused calves.(ABSTRACT TRUNCATED AT 250 WORDS)     

Endocrine,growth, and carcass characteristics of bulls immunized against luteinizing hormone-releasing hormone fusion proteins

This study evaluated the effectiveness of a LHRH fusion protein vaccine on endocrine changes, feedlot performance, and carcass quality of bulls compared with steers and hormone-implanted steers. Crossbred bulls (n = 30; mean weight, 179 +/- 4 kg; mean age, 130 +/- 2 d) were randomly assigned to three treatment groups: 1) castrated (castrated; n = 10); 2) castrated-implanted with trenbolone acetate (implanted; n = 10); and 3) immunized against a cocktail of recombinant fusion proteins, ovalbumin-LHRH-7 and thioredoxin-LHRH-7 (immunized bulls; n = 10). Blood was collected every 2 wk to evaluate antibody and hormone concentrations. Serum LHRH antibodies (P < 0.001) were detected in animals of the immunized group, which had reduced serum LH concentrations (P < 0.001) compared with the castrated groups and serum FSH concentrations, which did not decrease but were significantly different when compared with castrated and implanted animals. Serum testosterone concentrations in the immunized bulls were not different from the two castrated groups (P > 0.05) by d 60 after primary immunization. Initial mean scrotal circumference of the immunized bulls was 18.0 +/- 0.6 cm on d 0 and increased to 22.6 +/- 1.3 cm by d 310. No differences (P > 0.05) in ADG were observed among treatment groups. Immunized animals had an intermediate BW gain (P > 0.05) when compared with the castrates, whereas the castrated groups differed (P < 0.05) from each other. Carcass characteristics were similar (P < 0.05) among the three groups. Vaccinating bulls against a LHRH fusion protein cocktail suppressed LH and testosterone, which led to reduced testicular development and no bullock carcasses. Growth and carcass characteristics of the immunized animals were similar to the steers.     

Predicting carcass composition of beef cattle using ultrasound technology.

We evaluated 20 slaughtered cattle with ultrasound before hide removal to predict fat thickness and ribeye area at the 12th rib for possible use in carcass composition prediction. Carcasses were fabricated into boneless subprimals that were trimmed progressively from 2.54 to 1.27 to .64 cm maximum fat trim levels. Stepwise regression was used to indicate the relative importance of variables in a model designed to estimate the percentage of boneless subprimals from the carcass at different external fat trim levels. Variables included those obtained on the slaughter floor (ultrasound fat thickness and ribeye area; estimated percentage of kidney, pelvic, and heart [KPH] fat; and warm carcass weight) and those obtained from carcasses following 24 h in the chill cooler (actual fat thickness, actual ribeye area, estimated percentage of KPH fat, warm carcass weight, and marbling score). At all different subprimal trim levels, percentage KPH was the first variable to enter the model. In the models using measures taken on the slaughter floor, ultrasound fat thickness was the only other variable to enter the model. Ultrasound fat thickness increased R2 and decreased residual standard deviation (RSD) in models predicting subprimals at 2.54-cm maximum fat trim; however, at 1.27- and .64-cm trim levels, R2 and RSD increased. Models using the same two variables (except actual fat instead of ultrasound) in the cooler were similar to those using data from the slaughter floor. However, as more cooler measurement variables entered the models, R2 increased and RSD decreased, explaining a greater amount of the variation in the equation. Ultrasonic evaluation on the slaughter floor may be of limited application compared with the greater accuracy found in chilled carcass assessment.     

Relation of growth hormone response to growth hormone-releasing hormone to estimation of milk production via deuterium oxide dilution in beef cattle

Current methods of estimating milk production in beef cows can be time-consuming, labor-intensive, and subject to high variability. The weigh-suckle-weigh (WSW) method requires repeated separation of offspring from their dams. Machine milking requires that animals be acclimated to the equipment prior to the estimation. The objective of Exp. 1 was to validate a deuterium oxide (D2O) dilution method of estimating milk production in cattle. In Exp. 1, Holstein calves (n = 5) averaging 29+/-2 d of age and 52.6+/-2.5 kg (+/- SE) were used as the model. Blood was collected for baseline D2O measurements followed by an injection of 300 mg D2O/kg BW. Syringes were weighed before and after the injection to gravimetrically determine the dose. Another blood sample was collected after D2O was allowed to equilibrate with body water for 2 h, and on each of the next five consecutive days, prior to feeding. Actual milk intake was measured by disappearance (i.e., amount of milk replacer offered to the calf minus the amount refused). Deuterium oxide in plasma was measured by mass spectrometry and milk intake was computed from the disappearance curve of D2O in blood plasma for each calf. Accumulated milk intake estimated by D2O dilution was highly correlated (y = 0.9x + 0.6; R2 = 0.99; P < 0.001) with actual milk intake. The objectives of Exp. 2 were to determine whether 1) D2O dilution was comparable to a standard measure of milk production in beef heifers and 2) growth hormone (GH) response to GH-releasing hormone (GHRH) in heifers at weaning is predictive of subsequent milk production. Deuterium oxide dilution and WSW were compared using 14 first-calf Angus heifers and their calves. Deuterium oxide dilution was used to estimate milk production of 40 first-calf Angus heifers that had been challenged with GHRH at weaning. Results indicate that the D2O dilution method is correlated (R2 = 0.89; P = 0.04) to the WSW estimation of milk production. Growth hormone response to GHRH in weanling heifers is positively related (R2 = 0.22; P = 0.03) to their subsequent milk production. Deuterium oxide dilution in calves offers an additional approach to the estimation of milk production of the dam in typical beef cattle production settings.     

Response to a growth hormone-releasing hormone analog in heifers treated with recombinant growth hormone

Sixteen pregnant Holstein heifers (430kg) were used to determine the effect of long-term administration of a bovine growth hormone (bGH) made by recombinant DNA technology on the ability of a bolus injection of a growth hormone-releasing hormone analog (Ac-His-1, D-Ala-2, Nle-27, GHRH(1-29 NH2) to increase serum GH. Eight heifers received a daily intramuscular injection of bGH (50 mg/day) for 5 months while the other half received a daily injection of physiological saline (control) over the same period. On the last day of bGH treatment and 1, 5, 10 and 25 days after the cessation of bGH treatment, five heifers from each group were challenged with GHRH analog and the response to this releasing hormone analog was measured. Basal GH concentrations were elevated on the last day of treatment in bGH-treated heifers and declined to concentrations similar to control heifers by 1 day after cessation of treatment. Response to GHRH analog was impaired by bGH during the last day of treatment and one day later. Responsiveness returned to a level similar to controls by 5 days after the end of bGH treatment. Response to GHRH analog was lessened during the period of bGH treatment but there were no long term effects on the animals' ability to respond to the releasing hormone.     

电穿孔法转移GHRH(1-32)质粒在仔猪肌肉中表达对生产性能的影响

采用pcDNA3.0-GHRH(1-32)质粒,对断奶仔猪肌肉单次注射后电穿孔处理,观察对猪生产性能的影响。采用碱变性法提取pcDNA3.0-GHRH(1-32)质粒并定量。选取32日龄仔猪60头,公母各半,分别注射0(生理盐水)、1.0mg GHRH表达质粒,然后用电穿孔仪电击处理。结果表明,与对照组相比,试验组猪32日龄初始平均体质量无差异(P0.05),公猪67和98日龄平均体质量分别显著增加26.71%(P0.05)和21.31%(P0.05),而母猪呈增加趋势但差异不显著(P0.05);公猪32~67日龄日增重显著增加47.93%(P0.05),而母猪呈增加趋势但差异不显著(P0.05);试验组淘汰率降低20.04%,其中公猪淘汰率降低33.50%;试验组猪80、150和180日龄血清GHRH浓度分别显著增加13.64%(P0.05)、15.82%(P0.05)和11.36%(P0.05),血清中IGF-1浓度分别增加26.70%(P0.05)、4.31%(P0.05)和6.04%(P0.05),且母猪血清浓度增幅高于公猪;血清中其余激素(T3、T4、IL-2、IL-6)和IgG浓度也呈上升趋势等。本试验表明GHRH(1-32)表达质粒可提高猪生产性能。     

Growth hormone response to a novel growth hormone-releasing tripeptide in horses: interaction with gonadotropin-releasing hormone, thyrotropin-releasing hormone, and sulpiride

A series of experiments was performed to determine the factor(s) responsible for an apparent inhibition of GH secretion in mares administered the GH secretagogue EP51389 in combination with GnRH, thyrotropin-releasing hormone (TRH), and sulpiride. Experiment 1 tested the repeatability of the original observation: 10 mares received EP51389 at 10 microg/kg BW; five received TRH (10 microg/kg BW), GnRH (1 microg/kg BW), and sulpiride (100 microg/kg BW) immediately before EP51389, and five received saline. The mixture of TRH, GnRH, and sulpiride reduced (P = 0.0034) the GH response to EP51389, confirming the inhibitory effects. Experiment 2 tested the hypothesis that sulpiride, a dopamine antagonist, was the inhibitory agent. Twelve mares received EP51389 as in Exp. 1; six received sulpiride before EP51389 and six received saline. The GH responses in the two groups were similar (P > 0.1), indicating that sulpiride was not the inhibitory factor. Experiment 3 tested the effects of TRH and(or) GnRH in a 2 x 2 factorial arrangement of treatments. Three mares each received saline, TRH, GnRH, or the combination before EP51389 injection. There was a reduction (P < 0.0001) in GH response in mares receiving TRH, whereas GnRH had no effect (P > 0.1). Given those results, Exp. 4 was conducted to confirm that TRH was inhibitory in vivo as opposed to some unknown chemical interaction of the two compounds in the injection solution. Twenty mares received TRH or saline and(or) EP51389 or saline in a 2 x 2 factorial arrangement of treatments. Injections were given separately so that the two secretagogues never came in contact before injection. Again, TRH reduced (P < 0.0001) the GH response to EP51389. In addition, TRH and EP51389 each resulted in a temporary increase in cortisol concentrations. Experiment 5 tested whether TRH would alter the GH response to GHRH itself. Twelve mares received porcine GHRH at 0.4 microg/kg BW; six received TRH prior to GHRH and six received saline. After adjustment for pretreatment differences between groups, the GHRH-induced GH response was completely inhibited (P = 0.068) by TRH. Exp. 6 was a repeat of Exp. 5, except geldings were used (five per group). Again, pretreatment with TRH inhibited (P < 0.0001) the GH response to GHRH. In conclusion, TRH inhibits the GH response not only to EP51389 but also to GHRH in horses, and in addition to its known secretagogue action on prolactin and TSH it may also stimulate ACTH at the dosage used in these experiments.     

Exogenous human growth hormone-releasing factor and ovine somatotropin improve growth performance and composition of gain in lambs

The objectives of this study were 1) to compare intermittent subcutaneous administration of human growth hormone-releasing factor (hGRF) at two doses with a similar regimen of ovine somatotropin (oST) for effects on growth and composition of gain in growing lambs and 2) to determine whether increasing the dietary amino acid availability enhances response to oST or hGRF. Eighty crossbred ewe and wether lambs (25.5 kg live weight) were assigned randomly in pairs to receive four daily injections of excipient, 40 micrograms oST/kg BW, 5 micrograms hGRF/kg BW or 10 micrograms hGRF/kg BW for 42 (n = 80) or 56 (n = 40) d. Doses were adjusted weekly for BW. Mean plasma oST concentrations increased from 2.03 ng/ml prior to treatment to 20.64, 4.80 and 5.45 ng/ml with oST, 5 and 10 micrograms/kg hGRF doses, respectively. Lambs did not become refractory to hGRF. Cumulative gain increased approximately 18% with 7 wk of treatment with oST and the low dose of hGRF (both P less than .01), and feed efficiency improved 21% with oST and 18% with both doses of hGRF (both P less than .05). Carcass lipid accretion rate decreased 22% to 30% (P less than .001), and carcass protein accretion rate increased 30% to 36% (P less than .001) with hGRF and oST treatment, respectively. Addition of fishmeal to the diet at 4% to replace an equal amount of soy protein improved gain 8.5%; it improved efficiency 14.2% (P less than .05) across all treatments, and it significantly enhanced the effects of oST on feed efficiency (interaction P less than .12) and hind leg muscle weights.     

Commercial adaptation of ultrasonography to predict pork carcass composition from live animal and carcass measurements.

Live animal and carcass data were collected from market barrows and gilts (n = 120) slaughtered at a regional commercial slaughter facility to develop and test prediction equations to estimate carcass composition from live animal and carcass ultrasonic measurements. Data from 60 animals were used to develop these equations. Best results were obtained in predicting weight and percentage of boneless cuts (ham, loin, and shoulder) and less accuracy was obtained for predicting weight and ratio of trimmed, bone-in cuts. Independent variables analyzed for the live models were live weight, sex, ultrasonic fat at first rib, last rib, and last lumbar vertebra, and muscle depth at last rib. Independent variables for the carcass models included hot carcass weight, sex of carcass, and carcass ultrasonic measurements for fat at the first rib, last rib, last lumbar vertebra, and muscle depth at last rib. Equations were tested against an independent set of experimental animals (n = 60). Equations for predicting weight of lean cuts, boneless lean cuts, fat-standardized lean, and percentage of fat-standardized lean were most accurate from both live animal and carcass measurements with R2 values between .75 and .88. The results from this study, under commercial conditions, suggest that although live animal or carcass weight and sex were the greatest contributors to variation in carcass composition, ultrasonography can be a noninvasive means of differentiating value, especially for fat-standardized lean and weight of boneless cuts.     

Modulation of growth hormone-releasing factor-induced release of growth hormone from bovine pituitary cells

Growth hormone (GH)-releasing factor (GRF) at concentrations of 10−¹² through 10−⁷M for 6 hr linearly increased GH release (b₁ = 10.4 ± .3) from bovine anterior pituitary cells in culture. Maximum release of GH (262% above controls) occurred at 10−⁷M GRF. In contrast, GH release-inhibiting factor (SRIF) at 10−¹² through 10−⁵M had no effect on basal concentrations of GH. In a second experiment, as the proportion of SRIF relative to GRF increased. SRIF suppression of GRF-induced GH release from anterior pituitary cells increased. In a third experiment, anterior pituitary cells cultured in media containing fetal calf serum (FCS) were treated with cortisol (0 or 10 ng/ml media) for 24 hr before exposure to 10−¹³ through 10−⁷M GRF. GRF linearly increased GH secretion (b₁ = 7.4 ± .3) and cortisol augmented this response (b₁ = 10.5 ± .6). However, when cells were cultured in media containing dextran-charcoal treated FCS, cortisol did not alter GRF-induced GH release. Our results demonstrate that GH response of bovine anterior pituitary cells to GRF was modulated negatively by SRIF. However, augmentation of GRF-induced GH release by cortisol was evident only when cells were cultured in media supplemented with untreated FCS.